Autocrine regulation of glioblastoma cell cycle progression, viability and radioresistance through the VEGF-VEGFR2 (KDR) interplay

Cell Cycle

Volumn 7, Issue 16, 2008, Pages 2553-2561

  Knizetova, Petra ^a,b   Ehrmann, Jiri ^a   Hlobilkova, Alice ^a   Vancova, Iveta ^c   Kalita, Ondrej ^a   Kolar, Zdenek ^a   Bartek, Jiri ^a,b  

^a PALACKÝ UNIVERSITY   (Czech Republic)

^b DANISH CANCER SOCIETY RESEARCH CENTER   (Denmark)

^c INSTITUTE OF VIROLOGY   (Slovakia)

Author keywords

Astrocytoma; Autocrine signaling; Cell cycle; Cell survival; Glioblastoma; Ionizing radiation; Vascular endothelial growth factor

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHOLIPASE C; PROTEIN KINASE B; PROTEIN KINASE C; RAF PROTEIN; RECEPTOR BLOCKING AGENT; SU 1498; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 2;

ARTICLE; ASTROCYTE; ASTROCYTOMA CELL; AUTOCRINE EFFECT; CANCER CELL CULTURE; CELL CYCLE PROGRESSION; CELL FUNCTION; CELL GROWTH; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; ENDOTHELIUM CELL; ENZYME ACTIVATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; IONIZING RADIATION; MICROENVIRONMENT; NEUROBLASTOMA CELL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; RADIOSENSITIVITY; SIGNAL TRANSDUCTION; TUMOR GROWTH; UMBILICAL VEIN;

EID: 49749122191     PISSN: 15384101     EISSN: 15514005     Source Type: Journal    
DOI: 10.4161/cc.7.16.6442     Document Type: Article

References (44)

1. Olumi AF, Dazin P, Tlsty TD. A novel co-culture technique demonstrates that normal human prostatic fibroblasts contribute to tumor formation of LNCaP cells by retarding cell death. Cancer Res 1998; 58:4525-30.
2. Rubenstein JL, Kim J, Ozawa T, Zhang M, Westphal M, Deen DF, Shuman MA. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000; 2:306-14.
3. DeAngelis LM. Brain tumors. N Engl J Med 2001; 344:114-23.
4. Ohgaki H, Kleihues P. Epidemiology and etiology of astrocytomas. Acta Neuropathol 2005; 109:93-108.
5. Knizetova P, Darling J, Bartek J. Vascular endothelial growth factor in astroglioma stem cell biology and response to therapy. J Cell Mol Biol 2007; 12:111-25.
6. Fine HA, Figg WD, Jaeckle K, Wen PY, Kyritsis AP, Loeffler JS, Levin VA, Black PM, Kaplan R, Pluda JM, Yung WK. A Phase II trial of the anti-angiogenic agent thalidomide in patients with recurrent high-grade gliomas. J Clin Oncol 2000; 18:708-15.
7. Oehring RD, Miletic M, Valter MM, Pietsch T, Neumann J, Fimmers R, Schlegel U. Vascular endothelial factor (VEGF) in astrocytic gliomas-prognostic factor? J Neurooncol 1999; 45:117-25.
8. Gridley DS, Loredo LN, Slater JD, Archambeau JO, Bedros AA, Andres ML, Slater JM. Pilot evaluation of cytokine levels in patients undergoing radiotherapy for brain tumours. Cancer Detect Prev 1998; 22:20-9.
9. Termann BI, Dougher-Vermazen M, Carrion ME, Dimitrov DC, Armellino D, Gospodarowicz D, Bohlen P. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial growth factor. Biochem Biophys Res Commun 1992; 187:1579-86.
10. Langer I, Vertongen P, Perret J, Fontaine J, Atassi G, Robberecht P. Expression of Vascular Endothelial Growth Factor (VEGF) and VEGF Receptors in Human Neuroblastomas. Med Pediatr Oncol 2000; 34:386-93.
11. Graeven U, Fiedler W, Karpinski S, Ergun S, Likic N, Rodeck U, Schmiegel W, Hossfeld DK. Melanoma-associated expression of vascular endothelial growth factor and its receptors FLT-1 and KDR. J Clin Oncol 1999; 125:621-9.
12. Jussila L, Alitalo K. Vascular Growth factors and Lymphangiogenesis. Physiol Rev 2002; 82:673-700.
13. Gomes E, Papa L, Hao T, Rockwell P. The VEGFR2 and PKA pathways converge at MEK/ERK1/2 to promote survival in serum deprived neuronal cells. Mol Cell Biochem 2007; 305:179-90.
14. Ilan N, Mahooti S, Madri JA. Distinct signal transduction pathways are utilized during the tube formation and survival phases of in vitro angiogenesis. J Cell Sci 1998; 111:3621-31.
15. Steiner HH, Karcher S, Mueller MM, Nalbantis E, Kunze S, Herold-Mende C. Autocrine pathways of the vascular endothelial growth factor (VEGF) in glioblastomas multiforme: clinical relevance of radiation-induced increase of VEGF levels. J Neurooncol 2004; 66:129-38.
16. Hong X, Jiang F, Kalkanis SN, Zhang ZG, Zhang XP, deCarvalho AC, Katakowski M, Bobbitt K, Mikkelsen T, Chopp M. SDF-1 and CXCR4 are upregulated by VEGF and contribute to glioma cell invasion. Cancer Lett 2006; 236:39-45.
17. Herold-Mende C, Andl T, Steiner HH, Riede D, Buttler A, Reisse C, Fusenig NE, Mueller MM. Expression and functional significance of vascular endothelial growth factor receptors in human tumour cells. Lab Invest 1999; 79:1573-82.
18. Hovinga KE, Stalpers LJ, van Bree C, Donker M, Verhoeff JJ, Rodermond HM, Bosch DA, Furth WR. Radiation-enhanced vascular endothelial growth factor (VEGF) secretion in glioblastomas multiforme cell lines - a clue to radioresistance? J Neurooncol 2005; 74:99-103.
19. Reardon DA, Wen PY. The therapeutic advances in the treatment of glioblastoma: Rationale and potential role of the targeted agents. Oncologist 2006; 11:152-64.
20. Gorski DH, Beckett MA, Jaskowiak NT, Calvin DP, Mauceri HJ, Salloum RM, Seetharam S, Koons A, Hari DM, Kufe DW, Weichselbaum RR. Blockage of the Vascular Endothelial Growth Factor Stress Response Inreases the Antitumor Effects of Ionizing Radiation. Cancer Res 1999; 59:3374-8.
21. Shen BQ, Lee DY, Gerber HP, Keyt BA, Ferrara N, Zioncheck TF. Homologous upregulation of KDR/Flk-1 receptor expression by vascular endothelial growth factor in vitro. J Biol Chem 1998; 273:29979-98.
22. Bogler O, Mikkelsen T. Angiogenesis in glioma: molecular mechanisms and roadblocks to translation. Cancer J 2003; 9:205-13.
23. Samoto K, Ikezaki K, Ono M, Shono T, Khono K, Kuwavo M, Fukui M. Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 1995; 55:1189-93.
24. Damiano V, Melisi D, Bianco C, Raben D, Caputo R, Fontanini G, Bianco R, Ryan A, Bianco AR, De Placido S. Cooperative Antitumor Effect of Multi-targeted Kinase Inhibitor ZD6474 and Ionizing Radiation in Glioblastoma. Clin Cancer Res 2005; 11:5639-44.
25. Carmeliet P, Moons L, Luttun A, Vincenti V, Compernolle V, De Mol M, Wu Y, Bono F, Devy L, Beck H, Scholz D, Acker T, DiPalma T, Dewerchin M, Noel A, Stalmans I, Barra A, Blacher S, Vandendriessche T, Ponten A, Eriksson U, Plate KH, Foidart JM, Schaper WD, Charnock-Jones S, Hicklin DJ, Herbert JM, Désiré Collen D, Persico MG. Synergism between vascular endothelial growth factor and placental growth factor contributes to angiogenesis and plasma extravasation in pathological conditions. Nat Med 2001; 7:575-83.
26. Carmeliet P. Mechanisms of angiogenesis and arteriogenesis. Nat Med 2000; 6:389-95.
27. Ferrara N. VEGF: an update on biological and therapeutic aspects. Curr Opin Biotechnol 2000; 11:617-24.
28. Zachary I, Gliki G. Signaling transduction mechanisms mediating biological actions of the vascular endothelial growth factor family. Cardiovasc Res 2001; 49:568-81.
29. ARF, PTEN Tumor suppressor genes in Human Glioma Cells Lines. Brain Pathol 1999; 9:469-79.
30. Vivanco I, Sawyers CL. The phosphatidylinositol 3-kinase-Akt pathway in human cancer. Nat Rev Cancer 2002; 2:489-501.
31. Bartek J, Lukas J. DNA damage checkpoints: from initiation to recovery or adaptation. Curr Opin Cell Biol 2007; 19:238-45.
32. Bartkova J, Horejsi Z, Koed K, Krämer A, Tort F, Zieger K, Guldberg P, Sehested M, Nesland JM, Lukas C, Ørntoft T, Lukas J, Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005; 434:864-70.
33. Gorgoulis VG, Vassiliou LV, Karakaidos P, Zacharatos P, Kotsinas A, Liloglou T, Venere M, Ditullio RA Jr, Kastrinakis NG, Levy B, Kletsas D, Yoneta A, Herlyn M, Kittas C, Halazonetis TD. Activation of the DNA damage checkpoint and genomic instability in human precancerous lesions. Nature 2005; 434:907-13.
34. Kastan MB, Bartek J. Cell cycle checkpoints and cancer. Nature 2004; 432:316-23.
35. Bartek J, Lukas J, Bartkova J. DNA damage response as an anti-cancer barrier: damage threshold and the concept of 'conditional haploinsufficiency. Cell Cycle 2007; 6:2344-7.
36. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. Identification of a cancer stem cell in human brain tumors. Cancer Res 2003; 63:5821-8.
37. Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M, Kornblum HI. Cancerous stem cells can arise from pediatric brain tumors. Proc Natl Acad Sci USA 2003; 100:15178-83.
38. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. Identification of human brain tumour initiating cells. Nature 2004; 432:396-401.
39. Yuan X, Curtin J, Xiong Y, Liu G, Waschsmann-Hogiu S, Farkas DL, Black KL, Yu JS. Isolation of cancer stem cells from adult glioblastomas multiforme. Oncogene 2004; 23:9392-400.
40. Kondo T, Setoguchi T, Taga T. Persistence of a small subpopulation of cancer stem-like cells in the C6 glioma cell line. Proc Natl Acad Sci USA 2004; 101:781-6.
41. Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB, Dewhirst MW, Bigner DD, Rich JN. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 2006; 444:756-60.
42. Rich JN. Cancer Stem Cells in Radiation Resistance. Cancer Res 2007; 67:8980-4.
43. nd ed. Lyon: International Agency for Research on Cancer 2000; 29-39.
44. Ehrmann J, Rihakova P, Hlobilkova A, Kala M, Kolar Z. The expression of apoptosis-related proteins and the apoptotic rate in glial tumours of the brain. Neoplasma 2000; 45:117-25.